In these cases, topical and/or oral antibiotic/antiviral medications may need to be prescribed.Typical recommendations are:

Application of antiseptics
Soak in astringents
Antibiotics
Benzoyl peroxide
Topical diclofenac sodiumIf Dariers is more localized, common treatments include:
Topical retinoids: used to help in the reduction of hyperkeratosis, retinoids work by causing the skin cells in the top layers to die and be shed off. The common retinoids used for this disorder are:
Adapalene
Tazarotene gel
Tretinoin
Dermabrasion
Removal of the top layer of skin to help smooth and stimulate new growth of the skin. Electrosurgery
Used to help stop bleeding and remove abnormal skin growths. Topical corticosteroidsIf symptoms are severe, oral retinoids be prescribed and have been proven to be 90% effective. However, there can be many adverse side-effects associated with prolonged use. Common oral retinoids are:

Acitretin
Isotretinoin
CyclosporineSome patients are able to prevent flares with use of topical sunscreens and oral vitamin C.Further information on and advocacy work for Dariers disease are provided by the FIRST Skin Foundation. Epidemiology
Worldwide prevalence is estimated as between 1:30,000 and 1:100,000. Case studies have shown estimated prevalence by country to be 3.8:100,000 in Slovenia, 1:36,000 in north-east England, 1:30,000 in Scotland, and 1:100,000 in Denmark. History
Dariers disease was first described in a paper from 1917 by the dermatologist Ferdinand-Jean Darier in the French dermatological journal Annales de dermatologie et de syphilographie. Darier was a well-regarded dermatologist of the time who was the head of the medical department at the Hôpital Saint-Louis. Darier was an early proponent of histopathology, or the examination of samples of diseased flesh under a microscope to determine the cause of illnesses.
The trial targets patients under the age of 18 who have failed to improve on conventional treatments. This study was realised in the context of an EU-funded FP7 project, named FIGHT-HLH (306124). References
External links
"Emapalumab". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT01818492 for "A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis" at ClinicalTrials.gov